Articles On Invion (ASX:IVX)

The ASX posted steady gains to start the week on Monday, with investors preferences leaning towards tech/consumer stocks and gold (unusual bedfellows) at the expense of the big banks and iron ore majors. Companies that specialise in the pre...

The ASX had a positive finish to the week although it is in negative territory for the week. The ASX 200 closed at 7,443 points which is up 0.83% from yesterday but slightly down from the 7,457 mark it closed at last Friday. Today, the only...

Invion (IVX) ends the week in a trading halt while it plans the details of an upcoming capital raising The company will remain in the halt until November 16 or when more details are released, whichever occurs first On October 28, Invion r...

Life sciences outfit Invion is seeking $15 million to expand its technology licences for cancer treatment.

After a few weeks when the Hot Money column briefly turned into a ‘bizarro Viagold update’, the ASX put an end to that when it put the obscure rare earths play into suspension on October 15, pending “further enquiries”. This week a new lead...

After a positive Monday to Thursday, the ASX wiped out gains made across the week, losing more than 1% today The ASX followed a plunge on Wall Street with the ASX 200 closing at 7,324, which was 1.44% lower than yesterday’s close. While Wal...

Local stocks lost ground on Thursday, with minor falls at the big end of town and a slightly steeper drop of ~0.8% for the microcap Emerging Markets Index. The ASX opened with a weak lead from Wall Street, after a fortnight of steady gains...

The Invion Ltd (ASX: IVX) share price is on the move during late afternoon trade. This comes after the clinical-stage drug development company announced the pilot study results from its latest Proof-of-Concept (PoC) studies. At the time of...

A pilot proof-of-concept study by life sciences company Invion (ASX: IVX) has shown a complete regression of triple negative breast cancer (TNBC) in vivo following treatment with lead drug INV043. Conducted by Invion research partner Hudson...

Life sciences group Invion Group (ASX: IVX) has progressed the development of its next-generation photodynamic therapy for the treatment of various illnesses, boosted by part proceeds of a $4.5 million capital raising. In June, the company...

SYDNEY, Oct. 16, 2021 /PRNewswire/ — Ensuring healthy lives and promoting physical and mental well-being is essential to sustainable development. Currently, the world is facing a global health crisis unlike any other. Global health has i...

While Invion Group (ASX: IVX) progresses its next-generation photodynamic therapy INV043 for treating cancers, it is also advancing the therapy’s potential in combating bacterial, viral, fungal, parasitic diseases and atherosclerosis, which...

Life sciences company Invion Group (ASX: IVX) is rapidly advancing its next-generation photodynamic therapy INV043 for treating numerous cancers. The drug is under development in collaboration with the world-leading Hudson Institute of Medi...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

On the back of promising proof-of-concept results on a range of cancers, Invion Group (ASX: IVX) is looking to advance its novel photodynamic therapy (PDT) technology for the treatment of atherosclerosis and infectious diseases, and expand...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The armed forces could be called upon to enforce Sydney’s strict lockdown, and we might see troops on the streets as early as Monday. On the bourse, the benchmark ASX 200 has closed 0.40% lower on Friday, but was flat for the week. The mini...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

Small caps have dipped for a second straight day following their seven-day winning streak. The Small Ordinaries index closed yesterday down 12.1 points, or 0.37 per cent, to 3,278.8. Larger companies fared a little bit better, with the ASX2...

Investors will be watching for updates on Traka Resources (ASX:TKL) this week, after the gold explorer ripped higher on no news to post an RSI reading of 91. Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Re...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Summary Biopharmaceutical company Bionomics Limited will expand its product pipeline for the treatment of Social Anxiety Disorder (SAD). The Company disclosed that the rapid oral absorption of the novel tablet formulation of BNC210 is...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

A quick wrap of the ASX’s key winners and losers on Friday, September 4. Data is taken after the market closes at 4pm AEST. Today 298 stocks rose, 1,104 declined and 685 were unchanged. WINNERS Code Company Price % Change V...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

From the bulging file of Nasty Obscure Diseases we present idiopathic intracranial hypertension (IIH), a condition characterised by debilitating chronic daily headaches and in some cases severe vision impairment. It’s a poorly treated condi...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

03 Feb 2020 - A subsidiary of Invion (ASX:IVX), EpiTech Dermal Science, has signed an R&D services agreement with a leading China-based pharmaceutical group in the skin repair and …

When US Supreme Court judge Louis Brandeis in 1914 opined that sunlight was the best disinfectant, he was referring to the desirability of transparent legal and government processes. But he could well have been talking about the role of lig...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Invion (ASX:IVX) may have a new Chinese partner to help get its cosmetics business off the ground. The company told shareholders this morning it signed an MoU with Pavay Biotech, an established provider of dermatology treatment products in...

Telecommunications company Uniti Group (ASX:UWL) has topped the list of companies making their debut in 2019 with a whopping 500 per cent gain since listing. The internet service provider’s share price hit $1.50 last Friday to give it a $48...

Here’s our monthly wrap of all the news driving ASX health stocks. Of the ASX’s 137-odd small cap health stocks, 92 saw their share prices fall, 32 improved and 13 were flat. >> Scroll down for a table showing the performance of small...

Spies defecting, a foreign power secretly taking control of Australia via 5G, the stealthy infiltration of universities and CSIRO, a new arms race waged through cyber-warfare. This is not a John Le Carre novel, these are the headlines shapi...

Aerial imaging firm Aerometrex (ASX:AMX) has had a strong start to listed life on the ASX, notching a 107 per cent gain in its first two minutes on the bourse. The company doubled its IPO price of $1 on open before edging higher still to a...

While investing in the stock market, an investor comes across various classes of assets, such as equity and bonds. When it comes to investing in equity, there are choices like large-cap, mid-cap and small cap. Investment in small-cap comes...

By the closure of the market session on 29th November 2019, the benchmark index, i.e. S&P/ASX200 was at 6846 with a fall of 18 points from its last close. Besides the decline, some of the companies managed to trade in green and provided...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

For most stocks a double-digit gain in a single day is worthy of celebration. Invion Ltd [ASX:IVX] isn’t like most stocks though… This biotech minnow has made a huge splash today. The Invion share price posting as much as a 200% gain in ear...

One of the best performers on the Australian share market on Wednesday has been the Invion Ltd (ASX: IVX) share price. The clinical-stage drug development company’s shares rocketed an incredible 225% higher at one stage today. They have si...